TrialCancer medicine2025

A Phase II Pilot Study of Anti-PD-L1, Durvalumab, and a PARP Inhibitor, Olaparib in Patients With Metastatic Triple-Negative Breast Cancer With or Without Germline BRCA Mutation.

Takeo Fujii et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.